|
|
| 2003 |
Decoding of human genome opens door to cognitive research |
| 2004 |
Mouse model for DS developed by researchers in London; Down Syndrome Research and Treatment Foundation (DSRTF) is founded |
| 2005 |
DSRTF awards first grant to Dr. William Mobley of Stanford University |
| 2006 |
First drug target, the APP gene, identified by Dr. William Mobley and team, linking cognitive impairment in DS to the cognitive decline experienced in Alzheimer’s disease |
| 2007 |
DSRTF establishes it’s Scientific Advisory Board, the only scientific board in the US dedicated exclusively to cognition research for DS |
| 2008-2010 |
DSRTF expands grant awards to include Johns Hopkins University, UC San Diego, University of Arizona, University of Texas, and the VA Hospital of Palo Alto |
| 2011 |
Roche Pharmaceuticals begins clinical trial of the first potential therapy designed to improve cognition and adaptive behavior in individuals with Down syndrome |
| 2014 |
DSRTF renamed LuMind Foundation |
| 2015 |
Merged with Research Down Syndrome to create LuMind Research Down Syndrome Foundation, the largest source of private funding for DS cognition research |
| 2016 |
Awarded more than $13.2 million in research grants; 9 potential drug targets; 4 clinical trials |
| 2016 |
Awarded grant in first public private partnership with NIH, AC Immune for clinical trial |
